Prof. Sherven Sharma

University of California at Los Angeles, USA

Director

Email: [email protected], [email protected]

Qualifications

1996 Post-Doctorate Trainee, UCLA

1993 Ph.D., University of Southern California

1983 B.S., University of the South Pacific

Publications (selected)

1. Xu, Z. Y., Zhou, Z. H., Zhang, J., et al. (2021). Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis. Acta Pharmaceutica Sinica B, 11(5), 1274-1285.
2. Lisberg, A., Liu, B., Salehi-Rad, R., et al. (2021). Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC. Journal of Thoracic Oncology, 16(3, Suppl. S), S346-S347.
3. Kadam, P., Singh, R. P., Davoodi, M., et al. (2020). Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine. Vaccines, 8(4), Article 655.
4. Kadam, P., & Sharma, S. (2020). PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer. Vaccines, 8(2), Article 317.
5. Liu, B., Lisberg, A., Salehi-Rad, R., et al. (2020). Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC. Journal of Thoracic Oncology, 15(2, Suppl. S), S23.
6. Sharma, S., Kadam, P., & Dubinett, S. (2020). CCL21 Programs Immune Activity in Tumor Microenvironment. In A. Birbrair (Ed.), Tumor Microenvironment: The Role of Chemokines, Pt A (Vol. 1231, pp. 67-78). Springer.
7. Krysan, K., Tran, L. M., Grimes, B. S., et al. (2019). The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. Cancer Research, 79(19), 5022-5033.
8. Lisberg, A., Liu, B., Salehi-Rad, R., et al. (2019). Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC. Journal of Thoracic Oncology, 14(10, Suppl. S), S978.
9. Lim, R. J., Salehirad, R., Liu, B., et al. (2019). In situ vaccination with CCL21-modified dendritic cells (CCL21-DC) combined with checkpoint blockade in murine models of NSCLC. Cancer Research, 79(13, Suppl. S), Article 3214.
10. Liu, B., Garon, E. B., Lisberg, A. E., et al. (2019). A Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC. Cancer Research, 79(13, Suppl. S), Article CT226.
11. Tao, J. J., Fan, M. J., Zhou, D. F., et al. (2019). miR-200c Modulates the Pathogenesis of Radiation-Induced Oral Mucositis. Oxidative Medicine and Cellular Longevity, 2019, Article 2352079.
12. Walser, T. C., Jing, Z., Tran, L. M., et al. (2018). Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Research, 78(8), 1986-1999.
13. Xu, Z. Y., Tao, J. J., Chen, P., et al. (2018). Sodium Butyrate Inhibits Colorectal Cancer Cell Migration by Downregulating Bmi-1 Through Enhanced miR-200c Expression. Molecular Nutrition & Food Research, 62(6), Article 1700844.
14. Pellionisz, P. A., Lin, Y., Mallen-St Clair, J., et al. (2018). Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma. Otolaryngology-Head and Neck Surgery, 158(1), 110-117.
15. Wang, G. Y., Dong, F. L., Xu, Z. Y., et al. (2017). MicroRNA profile in HBV-induced infection and hepatocellular carcinoma. BMC Cancer, 17, Article 805.
16. Tan, Y.-H. C., Mirzapoiazova, T., Won, B. M., et al. (2017). Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Scientific Reports, 7, Article 9192.
17. Lee, J. M., Lee, M. H., Garon, E., et al. (2017). Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research, 23(16), 4556-4568.
18. Lee, J. M., Garon, E. B., Goldman, J. W., et al. (2017). Phase I Trial of CCL21 Gene Modified Dendritic Cells in Lung Cancer Elicits Immune Responses. Journal of Thoracic Oncology, 12(8, Suppl. S), S1537.
19. Salehi-Rad, R., Walser, T., Ong, S., et al. (2017). CCL21 Combined with PD-1 Blockade Cooperatively Inhibits Tumor Growth in KRAS Murine Model of NSCLC. Journal of Thoracic Oncology, 12(8, Suppl. S), S1537.
20. Sharma, S., & Dubinett, S. (2017). Inhibiting C5a/C5aR axis reduces myeloid-derived suppressor cells and enhances PD-1 blockade therapy in lung cancer. Translational Cancer Research, 6(Suppl. 6), S944-S948.

Profile Details

https://www.uclahealth.org/cancer/members/sherven-sharma

https://scholar.google.com/citations?user=B1ISfe8AAAAJ&hl=en

WOS ResearcherID: DQA-3912-2022